fingolimod hydrochloride has been researched along with Arrhythmia in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Aydinlar, A; Gullu, G; Gunay-Polatkan, S; Koc, ER; Sigirli, D; Turan, OF | 1 |
| El Sankari, S; Marchandise, S; Sindic, C; van Pesch, V | 1 |
| Cohen, JA; Collins, W; DiMarco, JP; Kappos, L; O'Connor, P; Reder, AT; Tang, D; Zhang-Auberson, L | 1 |
| Cartwright, E; Egom, EE; Ke, Y; Lei, M; Mohamed, TM; Musa, H; Solaro, RJ; Wang, T | 1 |
| Agoropoulou, C; Burtin, P; Calabresi, P; Hohlfeld, R; Kappos, L; Leyk, M; O'Connor, P; Polman, C; Radue, EW; Selmaj, K; Zhang-Auberson, L | 1 |
| Aradhye, S; Barkhof, F; Capra, R; Cohen, JA; Comi, G; de Vera, A; Gallo, P; Hartung, HP; Izquierdo, G; Jin, J; Kappos, L; Khatri, BO; Montalban, X; Pelletier, J; Stites, T; Tiel-Wilck, K; Wu, S | 1 |
| Carroll, WM | 1 |
| Bauersachs, J; Bonz, A; Burkard, N; Ertl, G; Frantz, S; Hofmann, U; Hu, K; Ritter, O; Walter, F | 1 |
| Cartwright, EJ; Chacko, S; Chirico, D; Egom, EE; Fath-Ordoubadi, F; Ke, Y; Lei, M; Liu, W; Mamas, MA; Mohamed, TM; Shaheen, M; Shi, Y; Solaro, RJ; Stringer, SE; Wang, T; Wang, X | 1 |
| Buja, LM; Haden-Pinneri, K; Lindsey, JW; Memon, NB | 1 |
| Bastien, MC; DiMarco, J; Hunt, TL; Kovarik, JM; Schmouder, R; Serra, D; Wang, Y | 1 |
4 trial(s) available for fingolimod hydrochloride and Arrhythmia
| Article | Year |
|---|---|
First-dose effects of fingolimod: Pooled safety data from three phase 3 studies.
Topics: Administration, Oral; Arrhythmias, Cardiac; Canada; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Injections, Intravenous; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome; United States | 2014 |
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Topics: Administration, Oral; Adolescent; Adult; Arrhythmias, Cardiac; Brain; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Fingolimod Hydrochloride; Herpesviridae Infections; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Liver Function Tests; Macular Edema; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Young Adult | 2010 |
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Topics: Administration, Oral; Adolescent; Adult; Arrhythmias, Cardiac; Brain; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Injections, Intramuscular; Intention to Treat Analysis; Interferon beta-1a; Interferon-beta; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Statistics, Nonparametric; Young Adult | 2010 |
FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects.
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography, Ambulatory; Exercise Test; Female; Fingolimod Hydrochloride; Heart Conduction System; Heart Rate; Humans; Immunosuppressive Agents; Male; Propylene Glycols; Reference Values; Sphingosine | 2006 |
7 other study(ies) available for fingolimod hydrochloride and Arrhythmia
| Article | Year |
|---|---|
Index of cardiac-electrophysiological balance in relapsing-remitting multiple sclerosis patients treated with fingolimod.
Topics: Arrhythmias, Cardiac; Electrocardiography; Fingolimod Hydrochloride; Heart; Heart Rate; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2023 |
Ventricular arrhythmia in a male MS patient on fingolimod.
Topics: Arrhythmias, Cardiac; Electrocardiography; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting | 2015 |
FTY720 prevents ischemia/reperfusion injury-associated arrhythmias in an ex vivo rat heart model via activation of Pak1/Akt signaling.
Topics: Animals; Animals, Newborn; Arrhythmias, Cardiac; Disease Models, Animal; Enzyme Activation; Fingolimod Hydrochloride; Gene Expression Regulation; In Vitro Techniques; Intracellular Space; Male; p21-Activated Kinases; Pertussis Toxin; Phosphorylation; Propylene Glycols; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Receptors, Lysosphingolipid; Reperfusion Injury; RNA, Messenger; Signal Transduction; Sinoatrial Node; Sphingosine; Time Factors; Ultrasonography | 2010 |
Oral therapy for multiple sclerosis--sea change or incremental step?
Topics: Administration, Oral; Arrhythmias, Cardiac; Cladribine; Disease Progression; Female; Fingolimod Hydrochloride; Herpesviridae Infections; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Male; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine | 2010 |
Pharmacological pre- and post-conditioning with the sphingosine-1-phosphate receptor modulator FTY720 after myocardial ischaemia-reperfusion.
Topics: Animals; Arrhythmias, Cardiac; Calcium; Disease Models, Animal; Down-Regulation; Fingolimod Hydrochloride; Ischemic Preconditioning, Myocardial; Lymphocyte Count; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocytes, Cardiac; Propylene Glycols; Rats; Rats, Wistar; Receptors, Lysosphingolipid; Sphingosine; Tumor Necrosis Factor-alpha | 2010 |
Activation of Pak1/Akt/eNOS signaling following sphingosine-1-phosphate release as part of a mechanism protecting cardiomyocytes against ischemic cell injury.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Animals; Arrhythmias, Cardiac; Biotransformation; Blotting, Western; Cardiotonic Agents; Cell Hypoxia; Cell Survival; Coronary Occlusion; Female; Fingolimod Hydrochloride; Humans; In Vitro Techniques; L-Lactate Dehydrogenase; Lysophospholipids; Male; Middle Aged; Myocardial Ischemia; Myocytes, Cardiac; Nitric Oxide; Nitric Oxide Synthase Type III; Oncogene Protein v-akt; p21-Activated Kinases; Pertussis Toxin; Propylene Glycols; Rats; Sphingolipids; Sphingosine | 2011 |
Sudden unexpected death on fingolimod.
Topics: Arrhythmias, Cardiac; Death, Sudden, Cardiac; Female; Fingolimod Hydrochloride; Humans; Hypertension; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine | 2012 |